UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures

Oncoimmunology, 2020-01, Vol.9 (1), p.1736792-1736792

2020

Volltextzugriff (PDF)

LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager

Frontiers in immunology, 2022-09, Vol.13, p.1008764-1008764

2022

Volltextzugriff (PDF)

Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist

Molecular cancer therapeutics, 2021-01, Vol.20 (1), p.96-108

2021

Volltextzugriff (PDF)

Tumor microenvironment mimicking 3D models unveil the multifaceted effects of SMAC mimetics

iScience, 2023-04, Vol.26 (4), p.106381-106381, Article 106381

2023

Volltextzugriff (PDF)

ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia

Cancer cell, 2018-03, Vol.33 (3), p.495-511.e12

2018

Volltextzugriff (PDF)

PolyI:C-induced reduction in uptake of soluble antigen is independent of dendritic cell activation

International immunology, 2009-07, Vol.21 (7), p.871-879

2009

Volltextzugriff (PDF)

Immunotherapy and immunoescape in colorectal cancer

World journal of gastroenterology : WJG, 2007-11, Vol.13 (44), p.5822

2007

Volltextzugriff (PDF)

Freeze-and-thaw-disrupted tumour cells impair the responsiveness of DC to TLR stimulation

European journal of immunology, 2008-10, Vol.38 (10), p.2740-2750

2008

Volltextzugriff (PDF)

Recombinant Adenoviral Vectors Turn on the Type I Interferon System without Inhibition of Transgene Expression and Viral Replication

Molecular therapy, 2006-07, Vol.14 (1), p.129-138

2006

Volltextzugriff (PDF)

Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma

Cancer research (Chicago, Ill.), 2006-02, Vol.66 (4), p.2442-2450

2006

Volltextzugriff (PDF)

Intratumoral Injection of Dendritic Cells Engineered to Secrete Interleukin-12 by Recombinant Adenovirus in Patients With Metastatic Gastrointestinal Carcinomas

Journal of clinical oncology, 2005-02, Vol.23 (5), p.999-1010

2005

Volltextzugriff (PDF)

Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses

Oncoimmunology, 2022-12, Vol.11 (1), p.2080328-2080328

2022

Volltextzugriff (PDF)

Dendritic cells delivered inside human carcinomas are sequestered by interleukin‐8

International journal of cancer, 2005-08, Vol.116 (2), p.275-281

2005

Volltextzugriff (PDF)

The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFNγ

International journal of cancer, 2007-09, Vol.121 (6), p.1282-1295

2007

Volltextzugriff (PDF)

Improving efficacy of interleukin‐12‐transfected dendritic cells injected into murine colon cancer with anti‐CD137 monoclonal antibodies and alloantigens

International journal of cancer, 2004-05, Vol.110 (1), p.51-60

2004

Volltextzugriff (PDF)

An anti-ICAM-2 (CD102) monoclonal antibody induces immune-mediated regressions of transplanted ICAM-2-negative colon carcinomas

Cancer research (Chicago, Ill.), 2002-06, Vol.62 (11), p.3167-3174

2002

Volltextzugriff (PDF)

Intratumoural administration of dendritic cells: hostile environment and help by gene therapy

Expert opinion on biological therapy, 2005-01, Vol.5 (1), p.7-22

2005

Volltextzugriff (PDF)

Potentiation of Therapeutic Immune Responses against Malignancies with Monoclonal Antibodies

Clinical cancer research, 2003-11, Vol.9 (15), p.5454-5464

2003

Volltextzugriff (PDF)

Anti-ICAM-2 Monoclonal Antibody Synergizes with Intratumor Gene Transfer of Interleukin-12 Inhibiting Activation-induced T-Cell Death

Clinical cancer research, 2003-09, Vol.9 (10), p.3546-3554

2003

Volltextzugriff (PDF)

Abstract 4558: In vitro and in vivo characterization of the PD-1 targeting antibody BI 754091

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4558-4558

2018

Volltextzugriff (PDF)

Abstract 4547: Characterization of the LAG-3 targeting antibody BI 754111 in monotherapy and in combination with the anti-PD-1 antibody BI 754091

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4547-4547

2018

Volltextzugriff (PDF)

Preclinical characterization of a potent and selective inhibitor of the histone demethylase KDM1A for MLL leukemia

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e13543-e13543

2013

Volltextzugriff (PDF)

The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFNy

International journal of cancer, 2007, Vol.121 (6), p.1282-1295

2007

Volltextzugriff (PDF)

Clinical implications of antigen transfer mechanisms from malignant to dendritic cells

Experimental hematology, 2002-12, Vol.30 (12), p.1355-1364

2002

Volltextzugriff (PDF)

Clinical implications of antigen transfer mechanisms from malignant to dendritic cells: Exploiting cross-priming

Experimental Hematology, 2002-12, Vol.30 (12), p.1355-1364

2002

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(29)
Dissertationen
(1)

Sprache

Englisch
(30)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures

LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager

Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist

Tumor microenvironment mimicking 3D models unveil the multifaceted effects of SMAC mimetics

ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia

PolyI:C-induced reduction in uptake of soluble antigen is independent of dendritic cell activation

Immunotherapy and immunoescape in colorectal cancer

Freeze-and-thaw-disrupted tumour cells impair the responsiveness of DC to TLR stimulation

Recombinant Adenoviral Vectors Turn on the Type I Interferon System without Inhibition of Transgene Expression and Viral Replication

Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma

Intratumoral Injection of Dendritic Cells Engineered to Secrete Interleukin-12 by Recombinant Adenovirus in Patients With Metastatic Gastrointestinal Carcinomas

Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses

Dendritic cells delivered inside human carcinomas are sequestered by interleukin‐8

The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFNγ

Improving efficacy of interleukin‐12‐transfected dendritic cells injected into murine colon cancer with anti‐CD137 monoclonal antibodies and alloantigens

An anti-ICAM-2 (CD102) monoclonal antibody induces immune-mediated regressions of transplanted ICAM-2-negative colon carcinomas

Intratumoural administration of dendritic cells: hostile environment and help by gene therapy

Potentiation of Therapeutic Immune Responses against Malignancies with Monoclonal Antibodies

Anti-ICAM-2 Monoclonal Antibody Synergizes with Intratumor Gene Transfer of Interleukin-12 Inhibiting Activation-induced T-Cell Death

Abstract 4558: In vitro and in vivo characterization of the PD-1 targeting antibody BI 754091

Abstract 4547: Characterization of the LAG-3 targeting antibody BI 754111 in monotherapy and in combination with the anti-PD-1 antibody BI 754091

Preclinical characterization of a potent and selective inhibitor of the histone demethylase KDM1A for MLL leukemia

The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFNy

Clinical implications of antigen transfer mechanisms from malignant to dendritic cells

Clinical implications of antigen transfer mechanisms from malignant to dendritic cells: Exploiting cross-priming

Suchergebnisse filtern